The global demand for Artificial Intelligence in Drug Screening Market is presumed to reach the market size of nearly USD 12.9 MN by 2028 from USD 1.79 MN in 2021 with a CAGR of 32.6% under the study period 2022 - 2028.
Artificial intelligence in drug screening is a vital process as drug abuse is a serious public health problem affecting an individual's brain and behaviour. Artificial intelligence in drug screening also plays a crucial role in the treatment of patients with drug addiction. It is employed in workplaces to avoid hiring drug addict candidates and provide a safe working environment to other employees.
Market Dynamics
The major factor driving the artificial intelligence in drug screening market growth includes an increase in alcohol consumption worldwide, a rise in the use of narcotics and illicit drugs across the globe, stringent government laws for drug screening, a rise in the adoption of AI systems, and technological innovations in the field of drug screening. Moreover, the market is expected to witness exponential growth during the forecast period, owing to the benefits of using these advanced techniques over traditional procedures. Furthermore, artificial intelligence reduces the cost and time utilized in the drug discovery process and boosts market growth. In addition, an increase in awareness related to artificial intelligence is expected to provide significant profitable opportunities for manufacturers in artificial intelligence for the drug screening industry. However, the shortage of the AI workforce and lack of data sets in the field of drug screening are some of the factors expected to hamper the market growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of artificial intelligence in drug screening. The growth and trends of artificial intelligence in drug screening industry provide a holistic approach to this study.
Market Segmentation
This section of the artificial intelligence in drug screening market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Technology
- Deep Learning
- Machine Learning
By Drug Type
- Small Molecule
- Large Molecules
By Disease Type
- Metabolic Disease
- Cardiovascular Disease
- Oncology
- Neurodegenerative Diseases
- Others
By End-Users
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Academic And Research Institutes
- Others
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Artificial Intelligence in Drug Screening market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Artificial Intelligence in Drug Screening Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the artificial intelligence in drug screening market include IBM Corporation, Microsoft, Atomwise Inc., Deep Genomics, Cloud Pharmaceuticals, Insilico Medicine, Benevolent AI, Exscientia, Cyclica and BIOAGE. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.